Clinical Trial Update: Sintilimab Combined With Stereotactic Body Radiotherapy as Neoadjuvant Therapy for Resectable Hepatocellular [Phase 2]

View source ↗

Summary

Phase 2 study evaluating sintilimab in combination with stereotactic body radiotherapy as neoadjuvant therapy for resectable hepatocellular carcinoma; the trial…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Sintilimab (sintilimab)

Snippet

Sponsor: Lei ZHAO | Conditions: HCC | Phase 2 | Status: NOT_YET_RECRUITING